Patents by Inventor Hideki Garren
Hideki Garren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230149395Abstract: Provided herein are methods of treating Relapsing Multiple Sclerosis (RMS) in a subject in need thereof, by administering to the subject about 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 1, 2021Publication date: May 18, 2023Applicants: Genentech, Inc., Hoffmann-La Roche Inc.Inventors: Hideki GARREN, Edmond Huatung TENG, Aurelien VIACCOZ, Hans-Christian VON BUEDINGEN
-
Publication number: 20230091561Abstract: Provided herein are methods of treating Primary Progressive Multiple Sclerosis (PPMS) in a subject in need thereof, by administering to the subject about 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 25, 2021Publication date: March 23, 2023Applicants: Genentech, Inc., Hoffmann-La Roche Inc.Inventors: Hideki GARREN, Edmond Huatung TENG, Aurelien VIACCOZ, Hans-Christian VON BUEDINGEN
-
Publication number: 20210388099Abstract: The present invention concerns methods for treating multiple sclerosis (MS) in a patient, and an article of manufac-ture with instructions for such use.Type: ApplicationFiled: March 16, 2021Publication date: December 16, 2021Inventors: David LEPPERT, Anne-Marie LI-KWAI-CHEUNG, Michele LIBONATI, Donna MASTERMAN, Jean-Paul PFEFEN, Craig SMITH, Algirdas Jonas Kakarieka WEISSKOPF, Jiameng ZHANG, Peter S. CHIN, Hideki GARREN
-
Publication number: 20190315827Abstract: The present invention provides compositions and methods for treating insulin-dependent diabetes mellitus in a subject comprising administration of a self-vector encoding and expressing human proinsulin.Type: ApplicationFiled: November 21, 2018Publication date: October 17, 2019Applicant: Tolerion, Inc.Inventors: Bart O. Roep, William H. Robinson, Paul Utz, Hideki Garren, Lawrence Steinman
-
Publication number: 20180327505Abstract: The present invention concerns methods for treating multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.Type: ApplicationFiled: April 5, 2018Publication date: November 15, 2018Inventors: David LEPPERT, Anne-Marie LI-KWAI-CHEUNG, Michele LIBONATI, Donna MASTERMAN, Jean-Paul PFEFEN, Craig SMITH, Algirdas Jonas Kakarieka WEISSKOPF, Jiameng ZHANG, Peter S. CHIN, Hideki GARREN
-
Publication number: 20180092991Abstract: This invention provides methods of treating insulin-dependent diabetes mellitus in a subject comprising administering to the subject a self-vector encoding human proinsulin. The invention also provides a pharmaceutical composition comprising a self-vector encoding human proinsulin, as well as treatment and maintenance regimens for administering the pharmaceutical composition to a subject.Type: ApplicationFiled: June 7, 2010Publication date: April 5, 2018Applicant: BAYHILL THERAPEUTICS, INC.Inventors: Hideki Garren, Michael Leviten, Nanette Solvason
-
Publication number: 20160068585Abstract: The present invention provides compositions and methods for treating insulin-dependent diabetes mellitus in a subject comprising administration of a self-vector encoding and expressing human proinsulin.Type: ApplicationFiled: May 1, 2014Publication date: March 10, 2016Inventors: Bart O. Roep, William H. Robinson, Paul Utz, Hideki Garren, Lawrence Steinman
-
Patent number: 8748404Abstract: A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-? and IL-15, are reduced.Type: GrantFiled: April 5, 2010Date of Patent: June 10, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Lawrence Steinman, Pedro Ruiz, Hideki Garren
-
Publication number: 20110034543Abstract: A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-? and IL-15, are reduced.Type: ApplicationFiled: April 5, 2010Publication date: February 10, 2011Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: LAWRENCE STEINMAN, PEDRO RUIZ, HIDEKI GARREN
-
Patent number: 7867976Abstract: Epitopic fragments of Nogo, including Nogo 45-66, elicit a specific and strong T cell response, and a B cell response. T cells reactive to Nogo antigens are capable of ameliorating ongoing disease, which may be induced with other antigens. The present invention provides compositions and methods for the identification and use of Nogo epitopic fragments in the treatment of immune related disease.Type: GrantFiled: May 14, 2004Date of Patent: January 11, 2011Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Lawrence Steinman, Hideki Garren, Paulo Fontoura
-
Publication number: 20100330110Abstract: This invention provides a method for determining the antibody specificity profile in an individual. This specificity profile reveals the individual's immune response to multiple antigens and/or epitopes of autoantigens, allergens, graft antigens, etc. The antibody specificity profile is determined through the binding of patient samples comprising antibodies to the arrays. The array can comprises antigens and epitopes. The invention also provides the means and methods for determining antigen or epitope specificity profiles that can be used in the development of either generic and individualized diagnosis and treatment for immune related diseases, including autoimmune disease, allergy and graft rejection.Type: ApplicationFiled: August 30, 2010Publication date: December 30, 2010Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: William H. Robinson, David L. Hirschberg, Lawrence Steinman, Pedro Jose Ruiz, Paul J. Utz, Hideki Garren
-
Patent number: 7811813Abstract: This invention relates to methods and compositions for treating or preventing disease comprising the administration of immune modulatory nucleic acids having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly the treatment and prevention of autoimmune or inflammatory diseases. The invention also relates to the treatment or prevention of disease comprising the administration of the immune modulatory nucleic acids alone or in combination with a polynucleotide encoding self-protein(s), -polypeptide(s) or -peptide(s). The present invention also relates to methods and compositions for treating diseases in a subject associated with one or more self-protein(s), -polypeptide(s) or -peptide(s) that are present in the subject and involved in a non-physiological state.Type: GrantFiled: November 21, 2003Date of Patent: October 12, 2010Assignees: The Board of Trustees of the Leland Stanford Junior University, Bayhill Therapeutics, Inc.Inventors: Hideki Garren, Peggy P. Ho, Lawrence Steinman
-
Patent number: 7785819Abstract: This invention provides a method for determining the antibody specificity profile in an individual. This specificity profile reveals the individual's immune response to multiple antigens and/or epitopes of autoantigens, allergens, graft antigens, etc. The antibody specificity profile is determined through the binding of patient samples comprising antibodies to the arrays. The array can comprises antigens and epitopes. The invention also provides the means and methods for determining antigen or epitope specificity profiles that can be used in the development of either generic and individualized diagnosis and treatment for immune related diseases, including autoimmune disease, allergy and graft rejection.Type: GrantFiled: April 10, 2002Date of Patent: August 31, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: William H. Robinson, David L. Hirschberg, Lawrence Steinman, Pedro Jose Ruiz, Paul J. Utz, Hideki Garren
-
Publication number: 20100160415Abstract: Disclosed are improved methods for the treatment or prevention of an autoimmune disease comprising administration of a modified self-vector encoding and capable of expressing a self-polypeptide that includes one or more pathogenic epitopes associated with the autoimmune disease. The improved method of the present invention includes the administration to a subject of a modified self-vector or self-vectors comprising a polynucleotide encoding a self-polypeptide. In one aspect, the method includes a modified self-vector that allows for increased expression of the self-polypeptide associated with an autoimmune disease in a host cell relative to the unmodified vector. In another, non-mutually exclusive aspect, the method includes a modified self-vector that allows for a secreted autoantigen associated with an autoimmune disease to be encoded as a non-secreted self-polypeptide.Type: ApplicationFiled: October 4, 2006Publication date: June 24, 2010Applicant: Bayhill Therapeutics, IncInventors: Nanette Solvason, Michael Leviten, Hideki Garren
-
Publication number: 20100130593Abstract: This invention relates to methods and compositions for treating or preventing disease comprising the administration of immune modulatory nucleic acids having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly the treatment and prevention of autoimmune or inflammatory diseases. The invention also relates to the treatment or prevention of disease comprising the administration of the immune modulatory nucleic acids alone or in combination with a polynucleotide encoding self-antigen(s), -proteins(s), -polypeptide(s) or -peptide(s). The present invention also relates to methods and compositions for treating diseases in a subject associated with one or more self-antigen(s), self-proteins(s), -polypeptide(s) or -peptide(s) that are present in the subject and involved in a non-physiological state.Type: ApplicationFiled: June 13, 2007Publication date: May 27, 2010Applicant: BAYHILL THERAPEUTICS, INC.Inventors: Hideki Garren, Michael Leviten, Nanette Solvason
-
Patent number: 7704970Abstract: A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-? and IL-15, are reduced.Type: GrantFiled: October 24, 2007Date of Patent: April 27, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Lawrence Steinman, Pedro Ruiz, Hideki Garren
-
Publication number: 20100048679Abstract: This invention provides methods of treating an autoimmune disease in a subject associated with one or more self-protein(s), polypeptide(s), or peptide(s) present in the subject non-physiologically comprising administering to the subject: a self-vector comprising an immunosuppressive vector backbone and a polynucleotide encoding the self-protein(s), polypeptide(s) or peptide(s) associated with the autoimmune disease; and a divalent cation at a concentration greater than physiological levels. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), polypeptide(s) or peptide(s) modulates an immune response to the self-protein(s), polypeptide(s) or peptide(s) expressed from administration of the self-vector This invention further provides a method of treating multiple sclerosis by administering a self-vector comprising a BHT-1 vector backbone, for example, self-vector BHT-3009 encoding human myelin basic protein (MBP).Type: ApplicationFiled: June 13, 2007Publication date: February 25, 2010Applicant: Bayhill Therapeutics, Inc.Inventors: Hideki Garren, Michael Leviten, Nanette Solvason
-
Publication number: 20090281170Abstract: This invention provides a method of treating or preventing a disease in an animal associated with one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present or involved in a non-physiologic process in the animal comprising administering to the animal a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) modulates an immune response to the self-protein(s), -polypeptide(s) or -peptide(s) expressed from administration of the self-vector.Type: ApplicationFiled: May 18, 2009Publication date: November 12, 2009Applicants: The Board of Trustees of the Leland Stanford Junior University, Bayhill Therapeutics/StanfordInventors: Paulo Fontoura, Hideki Garren, William H. Robinson, Lawrence Steinman, Pedro Jose Ruiz, Paul J. Utz
-
Publication number: 20090264515Abstract: This invention provides a method of treating or preventing a disease in an animal associated with one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present or involved in a non-physiologic process in the animal comprising administering to the animal a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) modulates an immune response to the self-protein(s), -polypeptide(s) or -peptide(s) expressed from administration of the self-vector.Type: ApplicationFiled: May 18, 2009Publication date: October 22, 2009Applicants: The Board of Trustees of the Leland Stanford Junior University, Bayhill Therapeutics/StanfordInventors: Paulo Fontoura, Hideki Garren, William H. Robinson, Lawrence Steinman, Pedro Jose Ruiz, Paul J. Utz
-
Patent number: 7585843Abstract: Compositions and methods are provided for the treatment or prevention of autoimmune disease. Therapeutic doses of one or more modified therapeutic ordered peptide(s) comprising amino acids representing a consensus sequence of a protein identified as a target of the autoimmune T and B cell response are described. Of particular interest are therapeutic ordered peptides of the autoantigens in multiple sclerosis, for example the myelin proteins MBP, MOG, PLP, MAG and cyclic nucleotide phosphodiesterase. The therapeutic ordered peptide may be extended at either termini by the addition of other D- or L- amino acid residues. The therapeutic ordered peptides may be administered topically or parenterally, by injection at a particular site, including subcutaneously, intraperitoneally, intravascularly, or the like or transdermally, as by electrotransport. The compositions of the invention may also contain other therapeutically active agents.Type: GrantFiled: October 1, 2004Date of Patent: September 8, 2009Assignee: Bayhill Therapeutics, Inc.Inventors: Hideki Garren, Stephanie Broome